Progress in cardiovascular diseases最新文献

{"title":"Subclinical atherosclerosis on chest computed tomography and mortality in young patients with severe hypercholesterolemia","authors":"Pamela Piña , Carol Fernandez , Daniel Lorenzatti , Francesco Castagna , Jeremy Miles , Toshiki Kuno , Andrea Scotti , Javier Arce , Carlos A. Gongora , Aldo L. Schenone , Matthew J. Budoff , Khurram Nasir , Ron Blankstein , Michael J. Blaha , Damini Dey , Daniel S. Berman , Jeffrey M. Levsky , Salim S. Virani , Mario J. Garcia , Leandro Slipczuk","doi":"10.1016/j.pcad.2023.11.002","DOIUrl":"10.1016/j.pcad.2023.11.002","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"List of recent issues","authors":"","doi":"10.1016/S0033-0620(23)00117-2","DOIUrl":"https://doi.org/10.1016/S0033-0620(23)00117-2","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138472016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in cardiac computed tomography","authors":"Afolasayo A. Aromiwura ,&nbsp;Tyler Settle ,&nbsp;Muhammad Umer ,&nbsp;Jonathan Joshi ,&nbsp;Matthew Shotwell ,&nbsp;Jishanth Mattumpuram ,&nbsp;Mounica Vorla ,&nbsp;Maryta Sztukowska ,&nbsp;Sohail Contractor ,&nbsp;Amir Amini ,&nbsp;Dinesh K. Kalra","doi":"10.1016/j.pcad.2023.09.001","DOIUrl":"10.1016/j.pcad.2023.09.001","url":null,"abstract":"<div><p><span>Artificial Intelligence (AI) is a broad discipline of computer science and engineering. Modern application of AI encompasses intelligent models and algorithms for automated data analysis and processing, data generation, and prediction with applications in visual perception, speech understanding, and language translation. AI in healthcare uses machine learning (ML) and other predictive analytical techniques to help sort through vast amounts of data and generate outputs that aid in diagnosis, clinical decision support, workflow automation, and prognostication. Coronary computed tomography angiography (CCTA) is an ideal union for these applications due to vast amounts of data generation and analysis during cardiac segmentation, coronary calcium scoring, plaque quantification, </span>adipose tissue<span><span> quantification, peri-operative planning, fractional flow reserve quantification, and cardiac event prediction. In the past 5 years, there has been an exponential increase in the number of studies exploring the use of AI for </span>cardiac computed tomography<span> (CT) image acquisition, de-noising, analysis, and prognosis. Beyond image processing, AI has also been applied to improve the imaging workflow in areas such as patient scheduling, urgent result notification, report generation, and report communication. In this review, we discuss algorithms applicable to AI and radiomic analysis; we then present a summary of current and emerging clinical applications of AI in cardiac CT. We conclude with AI's advantages and limitations in this new field.</span></span></p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10190202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of coronary artery calcium scores among patients referred for cardiac imaging tests","authors":"Alan Rozanski ,&nbsp;Donghee Han ,&nbsp;Robert J.H. Miller ,&nbsp;Heidi Gransar ,&nbsp;Piotr Slomka ,&nbsp;Sean W. Hayes ,&nbsp;John D. Friedman ,&nbsp;Louise E.J. Thomson ,&nbsp;Daniel S. Berman","doi":"10.1016/j.pcad.2023.10.005","DOIUrl":"10.1016/j.pcad.2023.10.005","url":null,"abstract":"<div><h3>Background</h3><p>While coronary artery calcium (CAC) can now be evaluated by multiple imaging modalities, there is presently scant study regarding how CAC scores may vary among populations of varying clinical risk.</p></div><div><h3>Methods</h3><p><span><span><span>We evaluated the distribution of CAC scores among three patient groups: 18,941 referred for CAC scanning, 5101 referred for diagnostic coronary CT angiography (CCTA), and 3307 referred for diagnostic </span>positron emission tomography (PET) </span>myocardial perfusion imaging (MPI). We assessed the relationship between CAC score and </span>myocardial ischemia<span>, obstructive coronary artery disease (CAD), and all-cause mortality across imaging modalities.</span></p></div><div><h3>Results</h3><p>Within each age group, the frequency of CAC abnormalities were relatively similar across testing modalities, despite an annualized mortality rate which varied from 0.5%/year among CAC patients to 3.8%/year among PET-MPI patients (<em>p</em><span> &lt; 0.001). Among CCTA<span> and PET-MPI patients, a zero CAC score was common, occurring in ~70% of patients &lt;50 years, ~40% of patients 50–59 years, and ~ 25% of patients 60–69 years. Among CCTA patients, zero CAC was associated with a normal coronary angiogram with high frequency, ranging from 92.2% among patients &lt;50 years to 87.9% among patients ≥70 years. Among PET-MPI patients, zero CAC was associated with a very low frequency of inducible ischemia across all age groups, ranging from 1.5% among patients &lt;50 years to 0.9% among patients ≥70 years.</span></span></p></div><div><h3>Conclusions</h3><p>In our study, relatively similar CAC scores were noted among patients varying markedly in mortality risk. Clinically, zero CAC scores predicted both a low likelihood of obstructive CAD and inducible myocardial ischemia in all age groups and were observed with high frequency across diagnostic testing modalities.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter edge-to-edge repair in mitral regurgitation: A comparison of device systems and recommendations for tailored device selection. A systematic review and meta-analysis","authors":"Basel F. Alqeeq ,&nbsp;Mohammed Al-Tawil ,&nbsp;Mohammed Hamam ,&nbsp;Mohammad Aboabdo ,&nbsp;Mohammed I. Elrayes ,&nbsp;Juergen Leick ,&nbsp;Mohamed Zeinah ,&nbsp;Assad Haneya ,&nbsp;Amer Harky","doi":"10.1016/j.pcad.2023.10.008","DOIUrl":"10.1016/j.pcad.2023.10.008","url":null,"abstract":"<div><h3>Background</h3><p><span><span>Mitral valve<span> transcatheter edge-to-edge repair (M-TEER) is a minimally invasive method<span> for the treatment of </span></span></span>mitral regurgitation (MR) </span>in patients with prohibitive surgical risks. The traditionally used device, MitraClip, showed both safety and effectiveness in M-TEER. PASCAL is a newer device that has emerged as another feasible option to be used in this procedure.</p></div><div><h3>Methods</h3><p>We searched for observational studies that compared PASCAL to MitraClip devices in M-TEER. The electronic databases searched for relevant studies were PubMed/MEDLINE, Scopus, and Embase. The primary outcomes were technical success and the grade of MR at follow-up. Secondary outcomes included all-cause mortality, bleeding, device success and reintervention.</p></div><div><h3>Results</h3><p>Technical success (PASCAL: 96.5% vs MitraClip: 97.6%, <em>p</em> = 0.24) and MR ≤ 2 at 30-day follow-up (PASCAL: 89.4vs MitraClip 89.9%, <em>p</em> = 0.51) were comparable between both groups. Both devices showed similar outcomes including all-cause mortality (RR: 0.68 [0.34, 1.38]; <em>P</em> = 0.28), major bleeding (RR: 1.87 [0.68, 5.10]; <em>P</em> = 0.22) and reintervention (RR: 1.02 [0.33, 3.16]; <em>P</em> = 0.97). Device success was more frequent with PASCAL device (PASCAL: 86% vs MitraClip 68.5%; <em>P</em> = 0.44), however, the results did not reach statistical significance.</p></div><div><h3>Conclusion</h3><p>Clinical outcomes of PASCAL were comparable to those of MitraClip with no significant difference in safety and effectiveness. The choice between MitraClip and PASCAL devices should be guided by various factors, including mitral valve anatomy, etiology of regurgitation, and device-specific characteristics.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the potential of ChatGPT for patient education in the cardiology clinic","authors":"Chayakrit Krittanawong ,&nbsp;Mario Rodriguez ,&nbsp;Scott Kaplin ,&nbsp;W.H. Wilson Tang","doi":"10.1016/j.pcad.2023.10.002","DOIUrl":"10.1016/j.pcad.2023.10.002","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease in space: A systematic review","authors":"Chayakrit Krittanawong ,&nbsp;Ameesh Isath ,&nbsp;Scott Kaplin ,&nbsp;Hafeez Ul Hassan Virk ,&nbsp;Sonya Fogg ,&nbsp;Zhen Wang ,&nbsp;Marc Shepanek ,&nbsp;Richard A. Scheuring ,&nbsp;Carl J. Lavie","doi":"10.1016/j.pcad.2023.07.009","DOIUrl":"10.1016/j.pcad.2023.07.009","url":null,"abstract":"<div><h3>Background</h3><p>With expanding commercial space programs, uncertainty remains about the cardiovascular effects<span><span> of space environmental exposures including microgravity, confinement, isolation, space radiation, and altered </span>bacterial virulence. Current limited data suggests additional health threats compared to Earth.</span></p></div><div><h3>Methods</h3><p>We systematically reviewed PubMed, CENTRAL, Web of Science, EMBASE and Cochrane databases for prospective studies on spaceflight and cardiovascular outcomes. Search terms combined cardiovascular disease topics with spaceflight concepts. No date or language restrictions were imposed.</p></div><div><h3>Results</h3><p>35 studies representing 2696 space travelers met inclusion criteria. Studies were grouped into spaceflight associations with: atherosclerosis<span><span>, mortality, cardiac function, orthostatic intolerance, and arrhythmias. Atherosclerosis evidence was limited, with animal studies linking space radiation to endothelial damage, </span>oxidative stress<span><span><span><span>, and inflammation. However, human data showed no significantly increased atherosclerotic disease in astronauts. Mortality studies demonstrated lower cardiovascular mortality in astronauts compared to the general population however there was conflicting data. Cardiac function studies revealed physiologic ventricular atrophy, increased </span>arterial stiffness, and altered blood flow distribution attributed to microgravity exposure. Effects appeared transient and reversible post-flight. Orthostatic intolerance studies found astronauts experienced altered </span>heart rate variability<span>, baroreflex response, and blood pressure changes post-flight. </span></span>Arrhythmia studies showed increased ventricular ectopy during spaceflight, but limited data on long term flights.</span></span></p></div><div><h3>Conclusions</h3><p>Environmental space hazards impact the cardiovascular system through multiple mechanisms. Microgravity causes cardiac atrophy and orthostatic intolerance while space radiation may potentially accelerate atherosclerosis. Further research is needed, especially regarding long-term spaceflights.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of patients with recurrent acute myocardial infarction after MINOCA","authors":"Giuseppe Ciliberti ,&nbsp;Federico Guerra ,&nbsp;Carmine Pizzi ,&nbsp;Marco Merlo ,&nbsp;Filippo Zilio ,&nbsp;Francesco Bianco ,&nbsp;Massimo Mancone ,&nbsp;Denise Zaffalon ,&nbsp;Rocco Gioscia ,&nbsp;Luca Bergamaschi ,&nbsp;Paolo Compagnucci ,&nbsp;Matteo Armillotta ,&nbsp;Michela Casella ,&nbsp;Angelo Sansonetti ,&nbsp;Marco Marini ,&nbsp;Pasquale Paolisso ,&nbsp;Giulia Stronati ,&nbsp;Sabina Gallina ,&nbsp;Antonio Dello Russo ,&nbsp;Gian Piero Perna ,&nbsp;Monica Verdoia","doi":"10.1016/j.pcad.2023.10.006","DOIUrl":"10.1016/j.pcad.2023.10.006","url":null,"abstract":"<div><h3><strong>Background</strong></h3><p>Myocardial infarction (MI) with non-obstructed coronary arteries<span> (MINOCA) is an increasingly recognized condition with challenging management. Some MINOCA patients ultimately experience recurrent acute MI (re-AMI) during follow-up; however, clinical and angiographic factors predisposing to re-AMI are still poorly defined.</span></p></div><div><h3><strong>Methods</strong></h3><p>In this retrospective multicenter cohort study we enrolled consecutive patients fulfilling diagnostic criteria of MINOCA according to the IV universal definition of myocardial infarction; characteristics of patients experiencing re-AMI during the follow-up were compared to a group of MINOCA patients without re-AMI.</p></div><div><h3><strong>Results</strong></h3><p>54 patients (mean age 66 ± 13) experienced a subsequent re-AMI after MINOCA and follow-up was available in 44 (81%). Compared to MINOCA patients without re-AMI (<em>n</em><span> = 695), on first invasive coronary angiography (ICA) MINOCA patients with re-AMI showed less frequent angiographically normal coronaries (37 versus 53%, </span><em>p</em><span> = 0.032) and had a higher prevalence of atherosclerosis involving 3 vessels or left main stem (17% versus 8%, </span><em>p</em> = 0.049).</p><p>Twenty-four patients (44%) with re-AMI underwent a new ICA: 25% had normal coronary arteries, 12.5% had mild luminal irregularities (&lt;30%), 20.8% had moderate coronary atherosclerosis (30–49%), and 41.7% showed obstructive coronary atherosclerosis (≥50% stenosis).</p><p>Among patients undergoing new ICA, atherosclerosis progression was observed in 11 (45.8%), 37.5% received revascularization, only 4.5% had low-density lipoprotein cholesterol (LDL_C) under 55 mg/dL and 33% experienced a new cardiovascular disease (CVD) event (death, AMI, heart failure, stroke) at subsequent follow-up.</p></div><div><h3><strong>Conclusions</strong></h3><p>In the present study, only a minority of MINOCA patients with re-AMI underwent a repeated ICA, nearly one out of two showed atherosclerosis progression, often requiring revascularization. Recommended LDL-C levels were achieved only in a minority of the cases, indicating a possible underestimation of CVD risk in this population.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher diet quality relates to better cardiac function in cancer survivors: The multi-ethnic study of atherosclerosis","authors":"Moriah P. Bellissimo ,&nbsp;Salvatore Carbone ,&nbsp;Jian He ,&nbsp;Jennifer H. Jordan ,&nbsp;Bharath Ambale-Venkatesh ,&nbsp;Joao A. Lima ,&nbsp;Jessica Gokee LaRose ,&nbsp;Fadi N. Salloum ,&nbsp;Dipankar Bandyopadhyay ,&nbsp;W. Gregory Hundley","doi":"10.1016/j.pcad.2023.10.004","DOIUrl":"10.1016/j.pcad.2023.10.004","url":null,"abstract":"<div><h3>Background</h3><p>Cancer therapies induce cardiac injury and increase cardiovascular disease (CVD) risk. In non-cancer populations, higher diet quality is associated with protection against CVD, but the relationship between diet and cardiac function in cancer survivors is unknown.</p></div><div><h3>Methods</h3><p>This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis<span><span> (MESA) cohort included 113 cancer survivors (55 breast, 53 prostate, three lung, and three blood) and 4233 non-cancer controls. Dietary intake was reported via validated food frequency questionnaire. Alternate healthy eating index (AHEI) was calculated as a measure of quality. Cardiac function, determined as </span>left ventricular ejection fraction<span> (LVEF), was assessed by cardiac magnetic resonance.</span></span></p></div><div><h3>Results</h3><p>Cancer survivors had a lower LVEF compared to controls (61.3 ± 6.5% v 62.4 ± 6.1%, <em>p</em> = 0.04). In all participants, total fat (β ± SE: −0.04 ± 0.01, <em>p</em><span> = 0.004), saturated fat (−0.11 ± 0.03, </span><em>p</em> &lt; 0.001), and trans-fat (−0.36 ± 0.12, <em>p</em><span> = 0.002) intake were inversely associated with LVEF while AHEI (0.03 ± 0.01, p &lt; 0.001) was positively associated with LVEF. Among cancer survivors only, sucrose intake was negatively related to LVEF (−0.15 ± 0.06, </span><em>p</em><span> = 0.02), and the ratio of unsaturated fat to saturated fat (2.7 ± 1.1, </span><em>p</em> = 0.01) and fiber intake (0.42 ± 0.14, <em>p</em> = 0.003) were positively related to LVEF.</p></div><div><h3>Discussion</h3><p>In cancer survivors, improved dietary fat and carbohydrate quality (i.e., greater consumption of unsaturated fatty acids and fiber) was associated with favorable cardiac function, while higher sucrose was associated with worse cardiac function. Further research is needed to confirm these findings and test whether changes in the identified dietary factors will modulate cardiac function in cancer survivors.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT inhibitors for improving Healthspan and lifespan","authors":"James H. O'Keefe,&nbsp;Robert Weidling,&nbsp;Evan L. O'Keefe,&nbsp;W. Grant Franco","doi":"10.1016/j.pcad.2023.10.003","DOIUrl":"10.1016/j.pcad.2023.10.003","url":null,"abstract":"<div><p>Sodium-glucose cotransporter inhibitor/inhibition (SGLTi), initially approved as a glucose-lowering therapy for type 2 diabetes, is associated with decreased risks for many of the most common conditions of aging, including heart failure, chronic kidney disease, all-cause hospitalization, atrial fibrillation, cancer, gout, emphysema, neurodegenerative disease/dementia, emphysema, non-alcoholic fatty liver disease, atherosclerotic disease, and infections. Studies also show that SGLTi improves overall life expectancy and reduces risks of cardiovascular death and cancer death. These wide-ranging health benefits are largely unexplained by the SGLTi’s modest improvements in standard risk factors. SGLTi produces upregulation of nutrient deprivation signaling and downregulation of nutrient surplus signaling. This in turn promotes autophagy, which helps to optimize cellular integrity and prevent apoptotic cell death. SGLTi decreases oxidative stress and endoplasmic reticulum stress, restores of mitochondrial health, stimulates mitochondrial biogenesis, and diminishes proinflammatory and profibrotic pathways. These actions help to revitalize senescent cells, tissues, and organs. In summary, SGLTi appears to slow aging, prevent disease, and improve life expectancy, and its mechanisms of action lend strong biological plausibility to this hypothesis. Further randomized trials are warranted to test whether SGLTi, a safe and well-tolerated, once-daily pill, might improve healthspan and lifespan.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0033062023001068/pdfft?md5=757e819bd78bc4fa452067abe8502eeb&pid=1-s2.0-S0033062023001068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}